Characterization and analysis of antibody domain-specific charge variants
Through digestive assisted imaging capillary electrophoresis, the problem of identifying and quantifying therapeutic peptide or protein charge variants is solved, and high sensitivity analysis of antibody domain-specific charge variants is achieved, ensuring the safety and effectiveness of the product.
Patent Information
- Application Number
- CN202080037901.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-05-23
- Filing Date
- 2020-05-23
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing methods are difficult to accurately identify and quantify domain-specific charge variants of therapeutic peptides or proteins, affecting their safety, effectiveness and shelf life.
Using digestion-assisted imaging capillary electrophoresis (DiCE) method, antibody fragments were generated by enzyme digestion and isoelectric focus electrophoresis under reducing and denaturation conditions to isolate and quantify the charge variants of the antibody, including the use of Streptococcus pyogenes immunoglobulin G Degradable enzymes, sialidases and other digestive enzymes, combined with reducing agents such as urea, guanidine hydrochloride and tris(2-carbonylethyl)phosphate hydrochloride.
High sensitivity methods are provided that accurately identify and quantify domain-specific charge variants of antibodies, evaluate their biophysical properties, and ensure product quality and safety of therapeutic peptides or proteins.
Smart Images

Figure BDA0003366751070000061 
Figure BDA0003366751070000171 
Figure HDA0003366751080000011
Abstract
Description
Technical Field
[0001] The present invention generally relates to antibody characterization methods and systems, including biophysical characterization assays for domain-specific variants. Background Art
[0002] The biophysical properties of therapeutic peptides and proteins, including those of domain-specific variants, may affect their safety, efficacy, and shelf life. For example, the presence of variants with different charges may alter solubility, binding, and stability.
[0003] Therapeutic peptides or proteins (such as antibodies) may acquire different variants and become heterogeneous due to various post-translational modifications (PTMs), protein degradation, enzymatic modifications, and chemical modifications. These changes in biophysical properties may occur at any time point during or after the production of peptides and proteins. Because these changes in biophysical properties may affect the safety, efficacy, and shelf life of therapeutic peptides and proteins, it is very important to identify different variants of a specific therapeutic peptide or protein and their associated safety, efficacy, and shelf life profiles.
[0004] It is recognized that there is a need for more efficient and accurate methods and systems for characterizing heterogeneity in therapeutic proteins. In addition, the methods and systems can provide valuable information for identifying charge variants that may be associated with specific binding capacity, biological activity, drug safety, and shelf life. Summary of the invention
[0005] The introduction of heterogeneity during the production of therapeutic peptides or proteins (such as antibodies) may cause concerns because it may affect the safety, efficacy and quality of the therapeutic protein. The present application provides biophysical properties of therapeutic peptides or proteins to analyze domain-specific variants of therapeutic peptides or proteins.
[0006] Exemplary embodiments disclosed herein meet the above needs by providing methods and systems for identifying or quantifying antibody charge variants using digestion-assisted imaging capillary electrophoresis (DiCE), including the use of isoelectric focusing to detect and quantify the levels of different domain-specific charge variants in antibodies (preferably in bispecific antibodies).
[0007] The present disclosure provides methods and systems for identifying at least one peptide or protein variant, comprising: treating at least one peptide or protein with one or more digestive enzymes to produce components of the at least one peptide or protein; reducing or denaturing the components of the at least one peptide or protein; and subsequently separating two or more components of the at least one peptide or protein.
[0008] In certain aspects, the digestive enzyme is Streptococcus pyogenes immunoglobulin G degrading enzyme, sialidase, cysteine protease, endopeptidase, papain, intracellular protease lysine-C, pepsin, trypsin, carboxypeptidase B, protease, or a combination thereof.
[0009] In certain aspects, the method of identifying variants of at least one peptide or protein further comprises treating the one or more components with one or more digestive enzymes in multiple phases to produce additional components.
[0010] In certain aspects, the reducing or denaturing conditions include the use of urea, guanidine hydrochloride, dithiothreitol (DTT), tris(2-carbonylethyl)phosphine hydrochloride (TCEP), an organic solvent, an alkaline solution, an acid solution, or a combination thereof.
[0011] In certain aspects, the components of the at least one peptide or protein are separated based on charge variants of the components, wherein the physical parameter is charge heterogeneity, molecular weight, charge, or a combination thereof.
[0012] In certain aspects, the components of the at least one peptide or protein are separated using isoelectric focusing, capillary isoelectric focusing, imaging capillary isoelectric focusing, chromatography-coupled capillary electrophoresis, chromatography-coupled imaging capillary electrophoresis, cation exchange chromatography, or liquid chromatography-mass spectrometry.
[0013] In certain aspects, the method of identifying charge variants of at least one peptide or protein further comprises generating a separation curve.
[0014] In certain aspects, the method of identifying charge variants of at least one peptide or protein further comprises quantifying the separated components of the at least one peptide or protein.
[0015] In certain aspects, the method of identifying charge variants of at least one peptide or protein further comprises identifying separate components of the at least one peptide or protein.
[0016] In certain aspects, the method of identifying charge variants of at least one peptide or protein further comprises identifying components of the at least one peptide or protein based on comparison of separation curves of at least one peptide or protein having different charge variants.
[0017] In other aspects, the method of identifying charge variants of at least one peptide or protein further comprises quantifying the level of glycation or C-terminal lysine of the recognition component.
[0018] In certain aspects, in the method of identifying charge variants of at least one peptide or protein, the at least one peptide or protein is a bispecific antibody.
[0019] In certain aspects, the at least one peptide or protein is a drug, an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug.
[0020] The present disclosure at least in part provides a system for identifying charge variants of at least one peptide or protein, comprising: at least one peptide or protein; a first digestive enzyme capable of producing said at least one peptide or protein component; an environment capable of reducing or denaturing said at least one peptide or protein component; and a device capable of separating said at least one peptide or protein component (which has been digested and reduced or denatured by one or more physical parameters in one or more capillaries).
[0021] In certain aspects, in the charge variant system for recognizing at least one peptide or protein, the environment further comprises a second digestive enzyme capable of processing the components of the at least one peptide or protein.
[0022] In certain aspects, in the system for recognizing charge variants of at least one peptide or protein, the first or second digestive enzyme is Streptococcus pyogenes immunoglobulin G degrading enzyme, sialidase, cysteine protease, endopeptidase, papain, intracellular protease lysine-C, pepsin, trypsin, carboxypeptidase B or protease.
[0023] In other aspects, in the system for identifying charge variants of at least one peptide or protein, the environment further includes a reducing agent or a denaturing agent, wherein the reducing agent or the denaturing agent is urea, guanidine hydrochloride, a reducing agent, dithiothreitol (DTT), tris(2-carbonylethyl)phosphine hydrochloride (TCEP), an organic solvent, an alkaline solution, an acid solution or a combination thereof.
[0024] In certain aspects, in the system for identifying charge variants of at least one peptide or protein, the device separates components based on one or more physical parameters in one or more capillaries, the physical parameters including (for example) charge heterogeneity, molecular weight, charge, or a combination thereof.
[0025] In certain aspects, the device is an isoelectric focusing device, a capillary isoelectric focusing electrophoresis instrument, an imaging capillary isoelectric focusing electrophoresis instrument, a chromatography-coupled capillary electrophoresis instrument, a chromatography-coupled imaging capillary electrophoresis instrument, a cation exchange chromatography device, or a liquid chromatography-mass spectrometry instrument.
[0026] In certain aspects, in the system for recognizing charge variants of at least one peptide or protein, the at least one peptide or protein is a bispecific antibody.
[0027] In certain aspects, in the system for recognizing charge variants of at least one peptide or protein, the at least one peptide or protein is a drug, an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment or a protein drug.
[0028] The above aspects and other aspects of the present invention can be better understood in conjunction with the following description and accompanying drawings. The following description provides various embodiments and numerous specific details thereof, which are intended to be examples only and not to limit the present invention. Many substitutions, modifications, additions or rearrangements may be made within the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1A MAB4 (Fc / Fc*) derived by the combination of the single heavy chains of MAB3 (Fc / Fc) and MAB1 (Fc* / Fc*) is shown. MAB3 has histidine (H) and tyrosine (Y) residues, and MAB1 has arginine (R) and phenylalanine (F) residues.
[0030] Figure 1B It is shown that MAB2 is a bispecific antibody targeting ANTIGENC and ANTIGENA. Glycosylation of MAB2 occurs at a single residue (ResidueX) in the CDR region of the ANTIGENC arm of the MAB2 heavy chain.
[0031] Figure 2 Antibodies subjected to enzymatic digestion are shown to produce antibody fragments, for example using Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) to produce F(ab')2 and Fc' fragments. Antibody fragments can be further subjected to reducing and / or denaturing conditions and analyzed using imaging capillary isoelectric focusing (icIEF) electrophoresis.
[0032] Figure 3 shows the results of a cation exchange chromatography (CEX, Figure 3A ), imaging capillary isoelectric focusing (icIEF, Figure 3B ) or chromatographic imaging capillary electrophoresis (chromiCE, Figure 3C ) Analysis of MAB4, MAB3 and MAB1.
[0033] Figure 4A The cleavage site of Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) is shown.
[0034] Figure 4B Results of testing for Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) cleavage efficiency, as analyzed by detecting the presence of intact antibody molecules and antibody fragments such as F(ab')2 and Fc', are shown below the peak area percentages.
[0035] Figure 5Aand 5B The digestion conditions for the Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) digestion reaction used to improve the efficiency of the enzyme digestion are shown, including 4 hours or overnight at 37°C to detect the presence of intact antibody molecules. Figure 5A In the Figure 5B In the figure, it is represented as a monomer.
[0036] Fig. 6A and 6B The estimated pi (isoelectric point) of MAB4, MAB3 and MAB1 is shown.
[0037] Fig. 7A and 7B Shown are the results of analysis of the Fc' fragment of MAB4, MAB3 or MAB1 after digestion with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) and icIEF analysis.
[0038] Fig. 8A Results of the analysis of the F(ab')2 fragment containing the VH domain are shown. The F(ab')2 fragment was purified and separated using icIEF and the experimental isoelectric point was determined after digestion with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS). The experimental isoelectric point of the intact antibody molecule was determined using icIEF, as shown in Figure 2. Figure 8B shown.
[0039] Fig. 9 Shown are the results of analysis of MAB4, MAB3 or MAB1 using DiCE under reducing and / or denaturing conditions to determine the experimental pi of Fc', F(ab')2, ANTIGENB-Fd', ANTIGENA-Fd' and LC (compared to the intact antibody molecule).
[0040] Fig. 10A Shown are the results of analysis of MAB4 using DiCE under reducing, denaturing conditions.
[0041] Fig. 10B Shown are the results of analysis of the F(ab')2 and Fc' fragments of MAB4 using icIEF under native conditions.
[0042] Fig.11A and 11B Results obtained using DiCE under reducing / denaturing conditions are shown.
[0043] Fig.12 Shown are triplicate analyses of MAB1, MAB4, and MAB3 using DiCE under reducing and denaturing conditions to determine the pI values of the corresponding peaks.
[0044] Fig.13Shown are triplicate analyses of MAB1, MAB4, and MAB3 using DiCE under reducing and denaturing conditions, and the area percentages of the corresponding peaks determined.
[0045] Fig.14 Shown is the recognition of the Fc / Fc* peak when the MAB4 Fc' fragment was treated with carboxypeptidase B (CPB).
[0046] Fig.15 Shown are the results of an analysis of MAB2 glycosylation using chromiCE.
[0047] Fig.16 Shown are the results of an analysis of glycosylation of MAB2 and its parental monospecific antibody using DiCE under reducing, denaturing conditions.
[0048] Fig.17A and 17B Shown are the results of analysis and enrichment of MAB2 glycosylated and non-glycosylated species using CEX and icIEF.
[0049] Fig.18A and 18B Shown are the results of analysis using DiCE under reducing, denaturing conditions comparing a glycated enriched sample to an enriched non-glycated sample (compared to MAB2). Fig.18A The relative abundance of the peaks is shown. Fig.18B The average peak area percentage corresponding to the peak number is shown.
[0050] Fig.19 Shown are the results of charge variant analysis using CEX and icIEF for samples obtained from two cell lines
[0051] Fig. 20 Shown are the results of charge variant analysis of samples obtained from two cell lines using DiCE under reducing, denaturing conditions.
[0052] Fig.21 Shown are the results of charge variant analysis of samples obtained from two cell lines using DiCE under reducing, denaturing conditions.
[0053] Fig. 22 Shown are the results of analysis of charge variants enriched by dual pH salt gradient cation exchange chromatography using intact icIEF.
[0054] Fig.23 Shown are the results of analysis of charge variants enriched by dual pH salt gradient cation exchange chromatography using DiCE.
[0055] Fig.24 Figure 2 is the result of DiCE analysis of MAB5 enriched charge variants.
[0056] Fig.25 This is the result of analyzing the combined Eb using DiCE. DETAILED DESCRIPTION
[0057] Due to the existence of charge variants in therapeutic proteins, people are concerned about drug efficacy, drug effectiveness and patient safety, because in some cases, the charge changes of therapeutic proteins may affect binding ability, biological activity and shelf life. The methods and systems of the present application can provide valuable information about the charge heterogeneity of therapeutic proteins, which has an impact on clinical pharmacology related to pharmacokinetics, efficacy and safety of drug administration (such as biologics administration).
[0058] The present disclosure provides methods and systems for analyzing the biophysical properties of peptides or proteins (such as antibodies) to meet the above needs. Enzyme digestion-assisted imaging capillary electrophoresis (DiCE) is used to characterize charge variants of peptides or proteins, such as domain-specific charge variants, preferably comparing charge variants between a bispecific antibody and its parent monospecific antibody. Variants can be characterized by biophysical parameters, including charge heterogeneity, molecular weight, charge, or a combination thereof. The methods and systems of the present application can be used for human immunoglobulins of all subclasses. The peptide or protein in the methods or systems of the present application can be a drug, an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug.
[0059] Therapeutic proteins (such as monoclonal antibody products) have abnormal heterogeneity due to various post-translational modifications, enzymatic and chemical modifications, such as glycosylation, deglycosylation, amidation, deamidation, oxidation, glycation, terminal cyclization, C-terminal lysine variation, C-terminal arginine variation, N-terminal pyroglutamate variation, C-terminal glycine amidation, C-terminal proline amidation, succinimide formation, sialylation or desialylation. In addition, aggregation, degradation, denaturation, fragmentation or isomerization of protein products can also cause charge heterogeneity. Table 1 shows typical chemical degradation pathways and their effects on changing the charge of peptides or proteins.
[0060] Table 1 Chemical degradation pathways of charge variants
[0061]
[0062] During the production of therapeutic peptides or proteins (e.g., monoclonal antibodies), charge heterogeneity may be introduced due to protein degradation and / or the presence of post-translational modifications (PTMs). Characterization of the charge variant forms of proteins in manufactured drug substances is necessary to fully understand the correlation between protein properties (e.g., potency) and the physical and chemical changes associated with charge variants.
[0063] Especially when producing monoclonal antibodies, PTMs in different domains of antibodies may cause different biological effects and may affect the stability, safety and efficacy of the drug product. Therefore, the characterization and routine monitoring of domain-specific modifications are very important to ensure the quality of therapeutic antibody products. Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) has been used to examine the heterogeneity of various domains in monoclonal antibody products. Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) can enzymatically cleave the antibody heavy chain below the hinge region to produce F(ab')2 and Fc' fragments. These antibody fragments can be further reduced to produce three antibody domains, such as LC (light chain), Fd' and Fc' / 2, for further characterization, such as analysis by liquid chromatography / mass spectrometry, capillary isoelectric focusing, glycan mapping or reversed phase chromatography. (An, Y et al. (2014) New tools for monoclonal antibody analysis. mAbs 6(4): 879-893).
[0064] The present application provides methods and systems based on DiCE (including isoelectric focusing) for detecting and quantifying the levels of different domain-specific charge variants in antibodies (including bispecific antibodies). In certain exemplary embodiments, these methods and systems include enzymatic digestion of F(ab')2 and Fc' fragments using Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS), followed by imaging capillary isoelectric focusing (icIEF) under reducing, denaturing conditions to separate LC, Fd' and Fc' / 2.
[0065] Advantages of the present invention include providing a highly sensitive DiCE-based method for detecting and quantifying domain-specific PTMs in different arms of bispecific antibodies. In certain exemplary embodiments, the DiCE-based method is used to detect and quantify site-specific glycosylation in the complementarity determining regions (CDRs) of bispecific antibodies targeting ANTIGENC and ANTIGENA. Cation exchange chromatography (CEX)) cannot accurately quantify the ResidueX site-specific glycosylation in the CDR of the ANTIGENC arm of the ANTIGENCxANTIGENA bispecific antibody. The advantages of the present application include providing a highly sensitive DiCE-based method for detecting antibody domain-specific charge variants to assess the level of unprocessed C-terminal lysine on the Fc domain.
[0066] The present application also provides a highly sensitive DiCE-based method or system for PTM quantification, the results of which are comparable to those obtained using peptide mapping. The methods and systems of the present application provide an orthogonal method comparable to peptide mapping in monitoring specific PTMs, ensuring product quality of therapeutic peptides and proteins such as antibodies, fusion proteins, antibody-drug conjugates (ADCs), and concomitantly administered antibodies-drug conjugates.
[0067] Advantages of the present application further include a DiCE-based method or system to analyze bispecific antibodies and their parent monospecific antibodies in independent analyses, which can provide a more comprehensive understanding of the domain-specific charge heterogeneity of bispecific antibody molecules. The use of enzymatic digestion in a DiCE-based method or system has the advantage of exposing the differences in the intrinsic charge of the generated antibody fragments by digesting the intact bispecific antibody. The method or system can more completely separate the generated antibody fragments or domains by isoelectric focusing.
[0068] The DiCE-based method or system of the present application can be applied to bispecific antibodies by providing a rapid, medium-throughput method to distinguish charge variants associated with multiple bispecific antibody arms, with a minimum sample size of less than 0.5 mg. The present application can also be used to accurately quantify the levels of certain post-translational modifications, such as glycation and untreated C-terminal lysine. The present application can be applied to products other than bispecific antibodies to more completely characterize other forms of charge variants, such as antibody-drug conjugates (ADCs) and combination products.
[0069] The method and system of the present application provide a kind of enzymatic digestion reaction to produce the component of peptide or protein.These components are the smaller fragments of peptide or protein.Subsequently, the component of peptide or protein can be separated according to the charge of peptide or protein component under reducing and / or denaturing conditions to analyze the charge heterogeneity of independent domains in peptide or protein.The component of peptide or protein can also be separated according to the difference of isoelectric point among the components, because these components belong to smaller fragments, the difference of isoelectric point between components is increased.
[0070] In certain exemplary embodiments, the bispecific antibody or its parent monospecific antibody undergoes an enzymatic digestion reaction to produce antibody fragments, such as F(ab')2 and Fc'. Isoelectric focusing can then be used to separate these antibody fragments according to their charge. In certain exemplary embodiments, these antibody fragments are further subjected to reduction and / or denaturation conditions to produce specific domains, such as LC, Fd' and Fc' / 2. These antibody domains can then be separated according to charge to analyze the charge heterogeneity of independent domains within the antibody. Because these domains have a smaller molecular weight than intact antibody molecules, the difference in isoelectric point between antibody domains enables separation based on measurable differences in isoelectric point. These antibody domains increase the difference in isoelectric point between the isoelectric points of the antibody domains.
[0071] In other exemplary embodiments, the present application provides a method for identifying charge variants of at least one peptide or protein, comprising: treating at least one peptide or protein with one or more digestive enzymes to produce components of at least one peptide or protein; reducing or denaturing the components of the at least one peptide or protein; and separating two or more components of the at least one peptide or protein, wherein isoelectric focusing is used to separate the components of the at least one peptide or protein according to the charge variants of the components. In certain aspects, separation curves of the components are generated and compared to detect or quantify the modification levels of the charge variants. They meet the long-standing need to characterize and quantify the charge heterogeneity of therapeutic proteins, which has an impact on clinical pharmacology related to the pharmacokinetics, efficacy and safety of drug administration.
[0072] Considering the limitations of existing methods, a sensitive and effective method for identifying, detecting or quantifying charge heterogeneity of therapeutic peptides or proteins was developed using a DiCE-based approach.
[0073] The term "a" means "at least one"; the terms "about" and "approximately" mean allowing for standard deviations understood by one of ordinary skill in the art; whenever a range is provided, the endpoints are included.
[0074] As used herein, the terms “include,” “includes,” and “including” are non-limiting and are to be read as “comprise,” “comprises,” and “comprising,” respectively.
[0075] In certain exemplary embodiments, the present disclosure provides a method for identifying variants of at least one peptide or protein, comprising: treating at least one peptide or protein with one or more digestive enzymes to produce components of at least one peptide or protein; reducing or denaturing the components of the at least one peptide or protein; and separating two or more components of the at least one peptide or protein according to the isoelectric points of the components. In certain exemplary embodiments, in the method for identifying charge variants of at least one peptide or protein, the at least one peptide or protein is a drug, an antibody, a bispecific antibody, a monoclonal antibody, a fusion protein, an antibody-drug conjugate, an antibody fragment, or a protein drug.
[0076] As used herein, the term "peptide" or "protein" includes any covalently linked amide bonded amino acid polymer. Proteins contain one or more amino acid polymer chains, commonly referred to in the art as "peptides" or "polypeptides". Proteins may contain one or more polypeptides, thereby forming a single functional biomolecule. In certain aspects, a protein may be an antibody, a multispecific antibody, an antibody fragment, a monoclonal antibody, a host cell protein, or a combination thereof.
[0077] In this article, "protein drug" includes active ingredients that are completely or partially biological in nature. In certain exemplary embodiments, the protein drug may include peptides, proteins, fusion proteins, antibodies, antigens, vaccines, peptide-drug conjugates, antibody-drug conjugates, protein-drug conjugates, cells, tissues, or combinations thereof. In other exemplary embodiments, the protein drug may include recombinant, transformed, modified, mutated, or truncated versions containing peptides, proteins, fusion proteins, antibodies, antigens, vaccines, peptide-drug conjugates, antibody-drug conjugates, protein-drug conjugates, cells, tissues, or combinations thereof.
[0078] As used herein, "antibody fragments" include a portion of a complete antibody, such as an antigen-binding region or an antibody variable region. Examples of antibody fragments include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, Fc fragments, scFv fragments, Fv fragments, dsFv bispecific antibodies, dAb fragments, Fd' fragments, Fd fragments, and independent complementarity determining regions (CDRs), as well as trispecific antibodies, tetraspecific antibodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed by antibody fragments. Fv fragments are combinations of immunoglobulin heavy and light chain variable regions, and scFv proteins are recombinant single-chain polypeptide molecules in which immunoglobulin light and heavy chain variable regions are connected by peptide linkers. Antibody fragments can be produced by different methods. For example, antibody fragments can be produced enzymatically or chemically by fragmentation of complete antibodies, and / or antibody fragments can be produced by genetic recombination encoding partial antibody sequences. In addition, antibody fragments can be produced by complete or partial synthesis. Antibody fragments can selectively include single-chain antibody fragments. In addition, antibody fragments can include multiple chains, such as those linked together by disulfide bonds. Antibody fragments may optionally comprise multimolecular complexes.
[0079] As used herein, the term “antibody-drug conjugate” or “ADC” refers to an antibody linked to a bioactive drug via a linker having a labile bond. ADCs may contain multiple bioactive drug molecules (or payloads) that may be covalently linked to the side chains of antibody amino acid residues (Siler Panowski et al., Site-Specific Antibody Drug Conjugates for Cancer Therapy, 6mAbs 34–45 (2013)). Antibodies used in ADCs are able to bind with sufficient affinity to selectively accumulate and persist at the target site. Most ADCs have Kd values in the nanomolar range. The payload potency may be in the nanomolar / picomolar range and may achieve achievable intracellular concentrations after the ADC is distributed to the target tissue. Finally, the linker forming the connection between the payload and the antibody is sufficiently stable in circulation to exploit the pharmacokinetic properties of the antibody moiety (e.g., long half-life), to allow the payload to attach to the antibody when distributed to the tissue, and to allow for efficient release of the bioactive drug after the ADC is taken up into the target cell. Linkers may include linkers that are not enzymatically cleavable during cell processing as well as linkers that are enzymatically cleavable once the ADC reaches the target site. For non-cleavable linkers, the bioactive drug released intracellularly includes the payload and all components of the linker that remain attached to the amino acid residues of the antibody (generally lysine or cysteine residues), followed by complete proteolytic degradation of the ADC within the lysosome. A cleavable linker is a linker that has a cleavage site between the payload and the amino acid attachment site on the antibody. The cleavage mechanism may include hydrolysis of acid-labile bonds in acidic intracellular compartments, cleavage of amide or ester bonds by intracellular proteases or esterases, and reductive cleavage of disulfide bonds by cells in a reducing environment.
[0080] As used herein, "antibody" refers to an immunoglobulin molecule consisting of four polypeptide chains, two heavy chains (H) and two light chains (L). Each heavy chain has a heavy chain variable region (HCVR or VH) and a heavy chain constant region. The heavy chain constant region consists of three domains (CH1, CH2 and CH3). Each light chain has a light chain variable region and a light chain constant region. The light chain constant region consists of a domain (CL). The VH and VL regions can be further subdivided into highly variable regions called complementarity determining regions (CDRs), and framework regions (FRs) interspersed in more conserved regions. Each VH and VL can be composed of three CDRs and four FRs, arranged in the following order from amino terminus to carboxyl terminus; FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The term "antibody" includes glycosylated and non-glycosylated immunoglobulins of any isotype or subclass. The term "antibody" includes, but is not limited to, antibodies prepared, expressed, created or isolated by recombinant means, such as antibodies isolated from host cells expressing the antibody following transfection. IgG comprises an antibody subgroup.
[0081] Exemplary Embodiments
[0082] Embodiments disclosed herein provide compositions, methods, and systems for identifying, detecting, or quantifying charge heterogeneity of therapeutic peptides or proteins using DiCE-based methods.
[0083] In certain exemplary embodiments, the present disclosure provides a method for identifying charge variants of at least one peptide or protein, comprising: treating at least one peptide or protein with one or more digestive enzymes to produce components of at least one peptide or protein; reducing or denaturing the components of the at least one peptide or protein; and separating two or more components of the at least one peptide or protein based on the charge heterogeneity of the charge variants. In certain aspects, the method for identifying charge variants of at least one peptide or protein can be used to quantify the modification level of the peptide or protein.
[0084] In certain exemplary embodiments, the modification of peptide or protein includes post-translational modification, enzymatic, chemical modification, aggregation, degradation, denaturation, fragmentation or isomerization. In some aspects, the modification of peptide or protein includes glycosylation, deglycosylation, amidation, deamidation, oxidation, saccharification, terminal cyclization, C-terminal lysine variation, C-terminal arginine variation, N-terminal pyroglutamate variation, C-terminal glycine amidation, C-terminal proline amidation, succinimide formation, sialylation, desialylation, adduct formation, disulfide-mediated modification, α-sialylation (terminal galactose) or C-terminal lysine and glycine amidation. In some aspects, the modification of peptide or protein includes the oxidation of methionine, cysteine, lysine, histidine or tryptophan.
[0085] In certain aspects, in the method for identifying charge variants of at least one peptide or protein, the digestive enzyme is Streptococcus pyogenes immunoglobulin G degrading enzyme, sialidase, cysteine protease, endopeptidase, papain, intracellular protease lysine-C, pepsin, trypsin, carboxypeptidase B, protease or a combination thereof. In certain aspects, about 100 μl of an antibody sample with a concentration of about 5 mg / mL is prepared in 1X DPBS (about 0.5 mg of total protein) and enzymatic digestion is performed using Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS).
[0086] In certain exemplary embodiments, peptide or protein components are separated based on the charge heterogeneity of the charge variants using isoelectric focusing, capillary isoelectric focusing, imaging capillary isoelectric focusing, chromatography-coupled capillary electrophoresis, chromatography-coupled imaging capillary electrophoresis, cation exchange chromatography, or liquid chromatography-mass spectrometry.
[0087] In certain exemplary embodiments, in the method for identifying the charge variant of at least one peptide or protein, the reducing or denaturing conditions include the use of urea, guanidine hydrochloride, dithiothreitol (DTT), tris (2-carbonyl ethyl) phosphine hydrochloride (TCEP), an organic solvent, an alkaline solution, an acid solution or a combination thereof. In certain aspects, about 1-10M guanidine hydrochloride, about 3-8M guanidine hydrochloride or preferably about 6M guanidine hydrochloride, plus about 1-50mM tris (2-carbonyl ethyl) phosphine hydrochloride (TCEP), about 5-15mM tris (2-carbonyl ethyl) phosphine hydrochloride (TCEP) or preferably about 10mM tris (2-carbonyl ethyl) phosphine hydrochloride (TCEP), cultured at room temperature for about 0.1-2 hours, about 0.5-1.5 hours or preferably about 1 hour, reducing the components of the peptide or protein or denaturing the components of the peptide or protein.
[0088] Subsequently, a buffer exchange is performed to remove the charged buffer components, preferably using a buffer comprising about 35 mM phosphate, about 8 M urea at a pH of about 6.0, and about 1 mM tris(2-carbonylethyl)phosphine hydrochloride (TCEP). The peptide or protein component is subjected to icIEF under the conditions of a composition preferably comprising about 21 mM phosphate, about 8 M urea at a pH of about 6.0, about 0.6 mM tris(2-carbonylethyl)phosphine hydrochloride (TCEP), about 0.35% (w / v) methylcellulose, about 4% (v / v) ampholytes at pH 3-10.
[0089] It should be understood that the method or system is not limited to the above-mentioned peptides, proteins, antibodies, protein drugs, digestive enzymes, reducing / denaturing conditions, isoelectric focusing electrophoresis, imaging capillary isoelectric focusing electrophoresis, chromatography-coupled capillary electrophoresis, chromatography-coupled imaging capillary electrophoresis, cation exchange chromatography or liquid chromatography-mass spectrometry.
[0090] The sequential labeling of method steps described herein with numbers and / or letters is not meant to limit the method or any embodiment described herein to the specific order shown.
[0091] This specification cites various publications, including patents, patent applications, published patent applications, accession numbers, technical literature and academic literature. These references become part of the present invention by reference.
[0092] The present disclosure may be more fully understood with reference to the following examples, which are provided to describe the present disclosure in more detail. These examples are intended to illustrate and should not be considered to limit the scope of the present disclosure.
[0093] Example
[0094] Materials and reagent preparation
[0095] 1.1. Monospecific and bispecific antibodies.
[0096] Several therapeutic antibodies, including bispecific antibodies and their parental monospecific antibodies, were biophysically characterized. Bispecific antibodies. The format of bispecific antibodies involves pairing two different heavy chains (HC) with two common light chains (LC), thereby achieving two unique antigen-binding sites for two different antigens. For example, MAB4 is a bispecific antibody targeting ANTIGENB and ANTIGENA. The ANTIGENA arm in the MAB4 heavy chain has two amino acid substitutions. Substitution of two amino acids in the Fc region of one of the MAB4 heavy chains disrupts protein A binding, such as replacing HY with RF, known as a star substitution or Fc*. This star substitution results in a difference in the theoretical isoelectric point between the unsubstituted and substituted heavy chains, which may help in the purification or separation of antibodies based on empirical (e.g., observational or experimental) isoelectric points.
[0097] MAB3 is a monospecific antibody targeting ANTIGENB, which has no star substitution in the heavy chain, such as Fc / Fc. MAB1 is a monospecific antibody targeting ANTIGENA, which has star substitution in both heavy chains, such as Fc* / Fc*. MAB4 is a bispecific antibody targeting ANTIGENB and ANTIGENA. MAB4 (Fc / Fc*) is composed of a single heavy chain of MAB3 (Fc / Fc) and a single heavy chain of MAB1 (Fc* / Fc*), such as Figure 1A Comparing the amino acid sequences between MAB3 and MAB1, they differ in the heavy chain Fc region, such as Figure 1A As shown. Figure 1A At the corresponding positions shown, MAB3 has histidine (H) and tyrosine (Y) residues, and MAB1 has arginine (R) and phenylalanine (F) residues.
[0098] MAB2 has about 40% glycosylation and is a bispecific antibody targeting ANTIGENC and ANTIGENA. Glycosylation of MAB2 occurs at a single residue ResidueX in the CDR region of the ANTIGENC arm of the MAB2 heavy chain, as Figure 1B As shown. Glycosylation of ResidueX affects drug activity and potency. The ANTIGENA arm of the MAB2 heavy chain is derived from the G parental germline with a star substitution in the Fc region.
[0099] 2.1 Enzymatic digestion of antibodies
[0100] Antibodies are digested by enzymes to produce antibody fragments, for example using Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) to produce F(ab')2 and Fc' fragments, such as Figure 2As shown. The F(ab')2 and Fc' fragments can be further subjected to reducing and / or denaturing conditions to produce antibody domains, such as LC, Fd' and Fc' / 2. For example, MAB4 (ANTIGENBxANTIGENA, Fc / Fc*) is digested with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) to produce F(ab')2 and Fc' fragments of MAB4. The F(ab')2 fragment of MAB4 is subjected to reducing and / or denaturing conditions to produce two Fd' (such as ANTIGENB-Fd' and ANTIGENA-Fd') and two light chains (LC). The Fc' fragment of MAB4 is subjected to reducing and / or denaturing conditions to produce two antibody domains, such as the ANTIGENB arm of Fc' and the ANTIGENA arm of Fc' (with a star substitution).
[0101] Isoelectric focusing instrument.
[0102] 1.1. Digestion-Assisted Imaging Capillary Electrophoresis (DiCE) workflow
[0103] The method for identifying the charge of a peptide or protein using DiCS comprises treating the peptide or protein with an enzyme digestion reaction to generate peptide or protein components, and separating the peptide or protein components according to the charge or isoelectric point of the components. Figure 2 An example of a general DiCE workflow using icIEF electrophoresis to separate bispecific antibodies fragmented using Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) is shown.
[0104] In certain exemplary embodiments, about 100 μl of an antibody sample with a concentration of about 5 mg / mL is prepared in 1X DPBS (about 0.5 mg of total protein) and enzymatically digested using Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS). The sample is then reduced and denatured by incubating at room temperature for about 1 hour using about 6 M guanidine hydrochloride and about 10 mM tris(2-carbonylethyl) phosphate hydrochloride (TCEP). The buffer is replaced with a buffer containing about 35 mM phosphate, about 8 M urea with a pH value of about 6.0, and about 1 mM tris(2-carbonylethyl) phosphate hydrochloride (TCEP) to remove charged buffer components. The sample is subjected to icIEF under the conditions of components containing about 21 mM phosphate, about 8 M urea with a pH value of 6.0, about 0.6 mM tris(2-carbonylethyl) phosphate hydrochloride (TCEP), about 0.35% (w / v) methylcellulose, and about 4% (v / v) pH 3-10 ampholytes. Undigested material was estimated to be less than 2% and did not affect peak quantification using DiCE.
[0105] Example 1. Analysis of antibody charge heterogeneity using CEX, icIEF, and chromiCE
[0106] Antibody charge heterogeneity was analyzed using CEX, icIEF, or chromatographic imaging capillary electrophoresis (chromiCE). The analysis was performed using therapeutic antibodies such as MAB4, MAB3, and MAB1, as shown in Figure 3.
[0107] CEX is used to analyze the surface charge of intact antibody molecules and provides low to medium resolution, such as Figure 3A icIEF is used to analyze the overall intrinsic charge of intact antibody molecules and provides high resolution and baseline separation based on the isoelectric point of the intact molecule, as shown in Figure 3B As shown. chromiCE is used to analyze the intrinsic charge of a single heavy chain (HC) and light chain (LC) of an antibody, wherein the antibody is analyzed under reducing and / or denaturing conditions. HC and LC are separated using size exclusion chromatography (SEC) under reducing and / or denaturing conditions, such as incubation for 1 hour in the presence of about 6 M guanidine hydrochloride and tris(2-carbonylethyl)phosphine hydrochloride (TCEP), followed by icIEF analysis. When there is a significant overlap between the isoelectric points of HC and LC, HC and LC cannot be completely separated, resulting in overlapping HC and LC peaks, such as Figure 3C As shown in Figure 4, the analytical results of CEX, icIEF, and chromiCE (like traditional charge-based assays) cannot distinguish the charge difference between the two unique heavy chains in a bispecific antibody.
[0108] When analyzing using intact icIEF under reducing and / or denaturing conditions, distinct peaks representing individual HCs can be detected and resolved. However, because the signals are convoluted into a single HC signal, charge differences between F(ab')2 and Fc' fragments cannot be distinguished. These charge variants include charge differences associated with post-translational modifications due to sequence differences in the VH domain or constant region (e.g., star substitutions).
[0109] Example 2. Antibody digestion with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS)
[0110] Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) is used to perform enzymatic digestion reactions at about 37°C for at least 2 hours. Under these conditions, the Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) digestion can effectively cleave immunoglobulin (IgG) molecules to produce antibody fragments, such as F(ab')2 and Fc', such as Figure 4A As shown. Several therapeutic antibodies (MAB9, MAB10, MAB5, MAB4, MAB1, and MAB3) were digested with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) and then subjected to icIEF analysis. The digestion efficiency of Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) was analyzed by detecting the presence of intact antibody molecules and antibody fragments (such as F(ab')2 and Fc'). Figure 4BAs shown, the digestion time was recorded to monitor the presence of high molecular weight (HMW) molecules. Compared with the AG lower hinge sequence, the GG lower hinge sequence had better enzyme digestion efficiency.
[0111] Test different digestion conditions for the Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) digestion reaction to improve the efficiency of the digestion, such as about 4 hours or overnight at 37°C. Figure 5B pyogenes immunoglobulin G degrading enzyme (IdeS) digestion efficiency as shown in Figure 5, including the presence of high molecular weight (HMW) molecules. Undigested MAB4 antibody was used as a control (denoted as Figure 5A The results showed that the enzyme cleavage efficiency was related to the molecule.
[0112] Example 3. Estimated isoelectric points in F(ab')2 and Fc' fragments
[0113] MAB4 (Fc / Fc*) is a bispecific antibody targeting ANTIGENB and ANTIGENA, which is composed of a single heavy chain of MAB3 (ANTIGENB, Fc / Fc) and a single heavy chain of MAB1 (ANTIGENA, Fc* / Fc*). Figure 1A As shown. There are differences between MAB3 and MAB1 heavy chains in the Fc region. Due to differences in the amino acid sequence, such as the amino acid substitution from HY to RF, the ANTIGENA heavy chain has a star substitution in the Fc region. The estimated pI (isoelectric point) of MAB4 shows that the ANTIGENB arm is more acidic than the bispecific antibody, while the ANTIGENA arm is more basic, as shown in Fig. 6A and 6B shown.
[0114] Example 4. Analysis of F(ab')2 and Fc' fragments
[0115] MAB4, MAB3, or MAB1 were subjected to enzymatic digestion, including treatment of the antibody with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) to produce antibody fragments, such as F(ab')2 and Fc' fragments. The antibody fragments were then separated based on their charge or isoelectric point. For the DiCE workflow, a protein concentration of approximately 0.3 mg was used. Under isoelectric focusing conditions, the ratio of ampholytes at pH 3-10 to ampholytes at pH 8-10.5 was approximately 3:1. Fig. 7A and 7BAs shown, according to the test results, the Fc' fragment of MAB1 is more basic compared to MAB4 and MAB3. The Fc' fragment of MAB3 is more acidic. The results show that the Fc' fragment of MAB1 is more basic due to the presence of two star-shaped substitutions, which is consistent with the pI estimation. The results also show that the Fc' fragment of MAB4 is more basic compared to MAB3 due to the presence of one star-shaped substitution in MAB4. In summary, the results show that the presence of one or two star-shaped substitutions is helpful in measuring the change in isoelectric point to detect domain-specific charge variants of bispecific antibodies. It was experimentally verified that the Fc' fragment with star-shaped substitutions is more basic than the native Fc' fragment in terms of overall charge, which is consistent with the pI prediction.
[0116] After digestion with S. pyogenes immunoglobulin G degrading enzyme (IdeS), the F(ab')2 fragments containing the VH domain were purified and isolated using icIEF to determine the experimental isoelectric point, as Fig. 8A The experimental isoelectric point of the intact antibody molecule was determined using icIEF. Figure 8B The results show that the experimental isoelectric point differences between the F(ab')2 fragments of MAB3, MAB4 and MAB1 correlate well with the differences between the corresponding intact antibody molecules. However, when the Fc' fragments were removed after digestion with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS), the separation of the F(ab')2 fragments using icIEF did not provide sufficient differentiation to distinguish the charge differences between the two heavy chains (such as with / without the star substitution).
[0117] Example 5. Analysis of Antibody Fragments under Reducing and / or Denaturing Conditions
[0118] Antibody fragments, such as F(ab')2 and Fc', were produced by digesting MAB3, MAB4 or MAB1 with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) at 37°C overnight (about 16 hours). The antibody fragments were then treated with about 6M guanidine hydrochloride and tris(2-carbonylethyl)phosphine hydrochloride (TCEP) for 1 hour to obtain four or five antibody domains, such as ANTIGENB-Fd', ANTIGENA-Fd', LC (light chain), ANTIGENB arm of Fc' and / or ANTIGENA arm of Fc'. These antibody fragments and domains were analyzed using icIEF to determine their experimental isoelectric points, such as Fig. 9 shown.
[0119] When MAB4 was digested with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) and analyzed by icIEF under reducing and / or denaturing conditions, the results showed five distinct peaks (distinguishable in isoelectric points) corresponding to Fc', LC, and two Fds, such as Fig. 10A shown. Fig. 10BShown are the results of analysis of F(ab')2 and Fc' fragments when MAB4 was digested with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) and analyzed by icIEF without reducing and / or denaturing conditions. Fig. 10A and 10B As a result, reducing and / or denaturing conditions emphasize differences in isoelectric points and are used to identify domain-specific charge variants of antibodies. In particular, three well-separated peaks corresponding to LC and two different Fd's are observed, such as Fig. 10A shown.
[0120] When MAB3 or MAB1 were digested with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) and analyzed by icIEF under reducing and / or denaturing conditions, the results showed three distinct peaks for each antibody (distinguishable by isoelectric point) corresponding to Fc', LC, and Fd', respectively. Fig.11A As shown. When comparing the peaks from the MAB3, MAB4, and MAB1 results, the three peaks in the MAB4 results can be identified as common LC, ANTIGENB-Fd', and ANTIGENA-Fd' from acidic to basic pIs. DiCE was performed on the parental monospecific monoclonal antibody and the purified Fc' and F(ab')2 fragments simultaneously to confirm the identity of the peaks. The experimental pI values of the Fd' fragments correlated well with the expected pI values of MAB4 and its parental monospecific antibody. We observed some overlap in the signals between the Fd' fragments. Some LC signals overlapped with the signal of the acidic Fd'. Overall, we observed three major peaks per fragment (or domain) that appeared nearly baseline separated.
[0121] The results showed that under reducing / denaturing conditions, the pH difference of Fd' obtained using DiCE was about 0.3-0.4 pH units, which is similar to the test results obtained using chromiCE. The pI range between HC obtained using chromiCE was about pH 6.8-7.6, with a difference of about 0.8 pH units. The pI range between Fd' fragments obtained using DiCE was about pH 7.5-8.0, with a difference of about 0.5 pH units.
[0122] like Fig.11A and 11B As shown, the results obtained using DiCE under reducing / denaturing conditions are complementary to those obtained using chromiCE. However, after analyzing the antibodies using DiCE under reducing / denaturing conditions, the results were able to demonstrate the presence of pi differences between the two heavy chains of the bispecific antibody, in particular between Fc' and Fd'.
[0123] To verify the reproducibility of the results using DiCE under reducing / denaturing conditions, three replicate injections were performed for MAB1, MAB4, and MAB3. Fig.12 and 13 The pI values of the corresponding peaks are highly reproducible, as shown in Fig.12 The peak area percentage of the corresponding peak is highly reproducible, as shown in Fig.13 shown.
[0124] To further identify the Fc / Fc* peaks, the purified MAB4 Fc' fragment was treated with carboxypeptidase B (CPB), which specifically cleaves the C-terminal lysine. The reduced abundance of peaks 5 and 6 indicates that these peaks contain unprocessed C-terminal lysine, such as Fig.14 shown.
[0125] Example 6. Recognition of Glycosylation in Bispecific Antibodies
[0126] MAB2 is a bispecific antibody targeting ANTIGENC and ANTIGENA. Glycosylation of MAB2 occurs at a single residue ResidueX in the CDR region of the MAB2 heavy chain ANTIGENC arm. Glycosylation of MAB2 could not be detected using icIEF analysis of intact antibody molecules. Although glycosylation of MAB2 could be detected using CEX, the test results obtained using CEX could not quantify the glycation level due to the poor resolution between the corresponding peaks of the glycated species and the adjacent peaks. Glycosylation of the heavy chain ANTIGENC arm was slightly visible in chromiCE and overlapped with the peak of the heavy chain (on the shoulder of the ANTIGENC heavy chain), as shown in Figure 5. Fig.15 Due to poor resolution, the glycosylation level of MAB2 could not be accurately quantified using chromiCE.
[0127] MAB2 and its parental monospecific antibodies (e.g., ANTIGENC and ANTIGENA monoclonal antibodies) were digested with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) and analyzed using DiCE under reducing / denaturing conditions. The test results of the three antibodies were compared side by side for peak identification, e.g. Fig.16 As shown. Peaks 1-6 were identified as corresponding to the Fc domain. Peak 8 was present in all samples and was identified as corresponding to the LC. Peak 11 was identified as representing the main anti-ANTIGENA Fd' fragment. Peaks 9-10 can represent the acidic form of anti-ANTIGENA Fd'. Anti-ANTIGENC Fd' fragments are shown as high-resolution split peaks, such as peaks 15 and 16, which can represent the glycosylated and non-glycosylated forms of ANTIGENC. Peaks 12-14 can represent the acidic form of the anti-ANTIGENC Fd' fragment.
[0128] To confirm the identity of peaks 15 and 16 corresponding to ANTIGENC, CEX was used to enrich the glycosylated and non-glycosylated species to homogeneity. The enriched glycosylated and non-glycosylated species had distinct and distinguishable curves in CEX, such as Fig.17A However, when using icIEF analysis, the peak curves are indistinguishable, as shown in Fig. 17B shown.
[0129] The enriched glycosylated and non-glycosylated species were digested with Streptococcus pyogenes immunoglobulin G degrading enzyme (IdeS) and analyzed using DiCE under reducing / denaturing conditions. Fig.18A As shown, compared with peak 16, the relative abundance of peak 15 (*) is higher in the glycated enriched samples and lower in the enriched non-glycated samples. Fig.18B The average peak area percentage corresponding to the peak number is shown.
[0130] Compared to peaks 15 and 16 shown in Table 2, non-glycated samples were enriched for peak 16. However, glycated enriched samples were enriched for peak 15. The relative abundance of peak 15 (*) was higher in glycated enriched samples, while the relative abundance of peak 16 increased in non-glycated samples. Based on the observation of two major ANTIGENC Fd' peaks, the quantification of glycated levels can be estimated by the relative ratio of peak 15 to the sum of peaks 15 and 16.
[0131] Table 2. Relative abundance of ANTIGENC Fd' peaks analyzed using DiCE.
[0132] Peak 15 Peak 16 Control MAB2-L26 4.1(0.2) 6.8(0.3) Non-glycated samples 0.6(0.1) 11.9(0.1) Glycosylated enriched samples 10.2(0.1) 2.1(0.1)
[0133] Peptide mapping was used to further validate the quantification of glycation levels in the MAB2 sample, as shown in Table 3. Table 3 shows the comparison of using CEX, peptide mapping, and DiCE. The results show that quantification using DiCE is comparable to peptide mapping.
[0134] Table 3. Quantification of glycation levels in MAB2 samples
[0135]
[0136] Example 7. Cell Line Development to Monitor Charge Variants
[0137] Cell lines used to produce antibodies were developed by monitoring charge variants of the antibodies produced. Cell line development was monitored using charge-based assays as a surrogate for various post-translational modifications (PTMs) that may be induced by the new cell line. Comparability of two cell lines (e.g., A28-L21 and A30-L91) was assessed using CEX and icIEF against C1 clinical comparator samples. Differences were observed between CEX and icIEF in the total abundance of charge basic variants, e.g. Fig.19 As shown, a slight increase in glycation was observed in A28-L21 compared to the control sample and A30-L91. Both C2 cell lines showed an increase in C-terminal lysines primarily on Fc*. When DiCE was used for selection of MAB2C2 cells, the samples showed a slight increase in Fc C-terminal lysines (peak 5), but a significant increase in Fc* C-terminal lysines (peak 6), as shown in Figure 2. Fig. 20 and 21 As shown. DiCE analysis showed that the increase in basic species observed in icIEF is due to the unprocessed C-terminal lysine on the Fc domain, while the Fc* domain is not susceptible to shearing. In addition, the glycosylation level of the A28-L21 clone is slightly higher than that generally observed in MAB2. DiCE can be used to quickly assess the glycosylation level of ANTIGENCs to support cell line and process development of MAB2.
[0138] Example 8. Monitoring post-translational modifications (PTMs)
[0139] The complete icIEF and DiCE profiles of the charge variants enriched by dual pH salt gradient cation exchange chromatography demonstrate the orthogonality between the two methods. While the peaks corresponding to the Fc / Fc*, LC, and ANTIGENA-Fd' fragments remain relatively constant across all samples, the distribution of the ANTIGENC Fd' peak (12-16) in the acidic fraction shows significant changes, as shown in Figure 2. Fig. 22 and 23 DiCE analysis of MAB2 enriched charge variants indicated that the ANTIGENC arm might be more susceptible to PTMs compared to the ANTIGENA arm.
[0140] Example 9. Analysis of MAB5 enriched charge variants using DiCE
[0141] DiCE was used to analyze the enriched charge variants of MAB5, e.g. Fig.24 As shown. Peaks 6, 8, and 11 represent the major charged species. Peak 6 corresponds to Fc. Peak 8 corresponds to LC. Peak 11 corresponds to the major Fd. Peaks 5 and 7 are particularly enriched in acidic 3. Peak 10 is the most abundant of the enriched basic 2 and may correspond to the MAB5 Fc fragment with an unprocessed C-terminal lysine.
[0142] Example 10. Analysis of combined Eb using DiCE
[0143] like Fig.25As shown, peaks 1-2 correspond to MAB6 LC. Peaks 3-5 correspond to Fc / 2 and are present in all samples. Peak 6 represents the LC of MAB7 and MAB8. Their sequences are almost identical. Peaks 7-8 correspond to MAB6 Fd fragment. Peak 9 corresponds to MAB7 Fd fragment. Peaks 10-11 correspond to MAB8 Fd fragment.
Claims
1. A method for identifying one or more charge variants of at least one bispecific antibody, comprising: treating the at least one bispecific antibody with one or more digestive enzymes to produce two or more components of the at least one bispecific antibody; reducing and denaturing the components; separating the two or more components of the at least one bispecific antibody based on intrinsic charge of the two or more components using digestion-assisted imaging capillary electrophoresis (DiCE), wherein a separation curve is generated; as well as The charge variants are identified.
2. The method according to claim 1, wherein: The digestive enzyme is Streptococcus pyogenes immunoglobulin G degrading enzyme, sialidase, cysteine protease, endopeptidase, papain, intracellular protease lysine-C, pepsin, trypsin, carboxypeptidase B, protease, exoglycosidase or a combination thereof.
3. The method according to claim 1, wherein: The reducing and denaturing conditions include using urea, guanidine hydrochloride, dithiothreitol (DTT), tris(2-carbonylethyl)phosphine hydrochloride (TCEP), an organic solvent, an alkaline solution, an acid solution or a combination thereof.
4. The method according to claim 1, wherein: The capillary electrophoresis method of DiCE is selected from: isoelectric focusing electrophoresis, capillary isoelectric focusing electrophoresis, imaging capillary isoelectric focusing electrophoresis, chromatography-coupled capillary electrophoresis, capillary electrophoresis, or chromatography-coupled imaging capillary electrophoresis.
5. The method of claim 1, further comprising quantifying or identifying the separated components of the at least one bispecific antibody.
6. The method of claim 1, further comprising identifying components of the at least one bispecific antibody based on comparison of separation curves of at least one bispecific antibody having different charge variants.
7. The method of claim 6, further comprising quantifying the level of the variant.
8. The method according to claim 7, wherein: Said variants of said at least one bispecific antibody include post-translationally modified variants.
9. The method according to claim 7, wherein: The variants of the at least one bispecific antibody include variants with glycated or unmodified C-terminal lysine from the components.
